Skip to main content

Table 1 Patient characteristics: Full Analysis Set

From: Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

Variable

RGB-02

(N = 121)

Reference

(N = 117)

Total

(N = 238)

Race [n (%)]

 White

120 (99.2)

117 (100)

237 (99.6)

 Asian

1 (0.8)

0

1 (0.4)

Age (years)

 Mean (std)

51.0 (8.20)

51.2 (9.56)

51.1 (8.88)

Weight (kg)

 Mean (std)

72.17 (14.049)

74.83 (15.240)

73.48 (14.676)

Height (cm)

 Mean (std)

163.3 (6.58)

163.5 (6.29)

163.4 (6.43)

BSA (m2)

   

 Mean (std)

1.791 (0.1718)

1.815 (0.1812)

1.803 (0.1765)

Stage of disease [n (%)]

 Stage IIB

58 (47.9)

56 (47.9)

114 (47.9)

 Stage III

61 (50.4)

60 (51.3)

121 (50.8)

Chemotherapy treatment [n (%)]

 Neoadjuvant

51 (42.1)

58 (49.6)

109 (45.8)

 Adjuvant

70 (57.9)

59 (50.4)

129 (54.2)

  1. BSA body surface area; std.standard deviation